1. LINE

      Text:AAAPrint
      Sci-tech

      Trials show China's mRNA COVID-19 vaccine safe, effective

      1
      2022-01-26 08:35:33Xinhua Editor : Li Yan ECNS App Download
      A medical worker injects a dose of COVID-19 vaccine at a vaccination site of Jingcheng Hospital in Ruili City, southwest China's Yunnan Province, April 1, 2021. (Xinhua/Chen Xinbo)

      A medical worker injects a dose of COVID-19 vaccine at a vaccination site of Jingcheng Hospital in Ruili City, southwest China's Yunnan Province, April 1, 2021. (Xinhua/Chen Xinbo)

      Special: Battle Against Novel Coronavirus

      A China-developed mRNA COVID-19 vaccine has been shown to be safe, well-tolerated and effective in early-stage human trials, according to a study published Tuesday in the Lancet Microbe journal.

      The vaccine ARCoV, which encodes the SARS-CoV-2 spike protein receptor-binding domain, was jointly developed by the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Yunnan-based Walvax Biotechnology Co., Ltd.

      Researchers conducted phase one trials at a hospital in Hangzhou, Zhejiang Province, from Oct. 30 to Dec. 2, 2020. A total of 120 healthy adults aged between 18 and 59 who tested negative for SARS-CoV-2 participated in the trials, which were randomized, double-blind and placebo-controlled.

      The vaccination procedure included two jabs, and five quantities of the vaccine were evaluated in the tests: 5 micrograms, 10 micrograms, 15 micrograms, 20 micrograms and 25 micrograms.

      The study highlighted that 15 microgram doses induced the highest titers of neutralising antibodies, roughly double the antibody titers of convalescent patients with COVID-19, indicating stronger immune responses induced by the vaccine.

      The vaccine candidate in these phase one trials exhibited an acceptable safety profile and induced a strong immune response in participants. No serious adverse events were reported within 56 days after vaccination, according to the study.

      A multi-regional phase three human trial with more participants is currently underway to test the efficacy of the Chinese vaccine.

      Two mRNA vaccines, developed by Moderna and Pfizer-BioNTech, have been approved for emergency use.

      China started building a plant to manufacture the mRNA vaccine in December 2020 in the city of Yuxi, Yunnan Province. It is expected to produce 120 million doses per year in its first phase.

      According to its developers, ARCoV was manufactured as a liquid formulation and can be stored in standard refrigerated conditions (2-8 degrees Celsius), which is convenient for transportation and application.

      MorePhoto

      Most popular in 24h

      MoreTop news

      MoreVideo

      LINE
      Back to top About Us | Jobs | Contact Us | Privacy Policy
      Copyright ©1999-2022 Chinanews.com. All rights reserved.
      Reproduction in whole or in part without permission is prohibited.
      [網上傳播視聽節目許可證(0106168)] [京ICP證040655號]
      [京公網安備 11010202009201號] [京ICP備05004340號-1]
      主站蜘蛛池模板: eeuss影院免费92242部| 欧洲亚洲综合一区二区三区| 日韩精品无码免费专区网站| 亚洲av高清在线观看一区二区 | 成人妇女免费播放久久久| 亚洲国产精品无码久久九九| 美女黄色毛片免费看| 亚洲精品国产日韩无码AV永久免费网| 午夜在线免费视频 | 卡1卡2卡3卡4卡5免费视频 | 免费精品久久久久久中文字幕| 日韩一区二区三区免费体验| 亚洲av无码兔费综合| 日韩精品亚洲专区在线观看| 美女露100%胸无遮挡免费观看| 亚洲高清无码在线观看| 三年片免费高清版| 久久久久亚洲精品无码蜜桃 | 免费在线观看自拍性爱视频| 亚洲精品视频久久久| 三根一起会坏掉的好痛免费三级全黄的视频在线观看 | 亚洲国产成人久久综合区| 人体大胆做受免费视频| 亚洲狠狠婷婷综合久久久久 | 亚洲伊人久久大香线蕉苏妲己| 91高清免费国产自产拍2021| 亚洲欧洲另类春色校园网站| 日韩在线天堂免费观看| jizz免费观看| 亚洲国产成人综合| 亚洲AV无码一区二区三区国产| 福利免费在线观看| 亚洲a级在线观看| 亚洲福利视频一区二区| 91香蕉国产线观看免费全集| 亚洲AV无码专区在线电影成人| 亚洲色一色噜一噜噜噜| 51视频精品全部免费最新| 欧美亚洲精品一区二区| 亚洲av伊人久久综合密臀性色 | 亚洲高清成人一区二区三区|